학술논문

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
Document Type
Article
Source
In: eClinicalMedicine. (eClinicalMedicine, October 2023, 64)
Subject
Language
English
ISSN
25895370